Who is sponsoring NCT05955170?

NCT05955170 is sponsored by Institut Curie.

What drugs are being tested in NCT05955170?

Interventions in NCT05955170: Tucatinib in Combination of Oral VP16 and trastuzumab.

What condition does NCT05955170 study?

NCT05955170 studies HER2-positive Breast Cancer.

Is NCT05955170 still recruiting?

NCT05955170 is currently recruiting now. Last updated 27 March 2025.

Last reviewed 2025-03-27 · How we verify

NCT05955170: TUC-TOC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

Recruiting now Phase 2 Last updated 27 March 2025

What this trial tests

Phase 2 trial testing Tucatinib in Combination of Oral VP16 and trastuzumab in HER2-positive Breast Cancer in 66 participants. Currently enrolling.

Timeline

19 December 2023

Primary endpoint
19 December 2027

19 December 2028

Quick facts

Lead sponsor	Institut Curie
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	19 December 2023
Primary completion	19 December 2027
Estimated completion	19 December 2028
Sites	13 locations across France

Drugs / interventions tested

Tucatinib in Combination of Oral VP16 and trastuzumab — full drug profile →

Conditions studied

HER2-positive Breast Cancer — all drugs for HER2-positive Breast Cancer →

Sponsor

Institut Curie — full company profile →

Who can join

18 and older, any sex, with HER2-positive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Novel HER-2 Targeted Therapies in Breast Cancer.
Fernandes CL, Silva DJ, Mesquita A. · · 2023 · cited 9× · PMID 38201515 · DOI 10.3390/cancers16010087

Verify or expand the search:

Other recruiting trials for HER2-positive Breast Cancer

Currently open trials in the same condition.

NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07377643 — IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer · Phase 3 · recruiting
NCT07510802 — Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC · Phase 1, PHASE2 · recruiting
NCT07486089 — Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) · Phase 1, PHASE2 · recruiting
NCT07102381 — A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Ca · Phase 2 · recruiting

Other Institut Curie trials

Trials by the same sponsor.

NCT07357948 — Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy · NA · not yet recruiting
NCT07491380 — Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TD · NA · not yet recruiting
NCT07193394 — Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · Phase 2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
NCT06659705 — Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05955170 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Curie
Last refreshed: 27 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05955170.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing